Balyasny Asset Management LLC Sarepta Therapeutics, Inc. Put Options Transaction History

Balyasny Asset Management LLC

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q4 2023 Feb 14, 2024	SELL	$67.31 - $124.76 $6.17 Million - $11.4 Million	-91,600 Reduced 67.65%	43,800 $4.22 Million
Q2 2023 Aug 14, 2023	SELL	$106.4 - $157.19 $11.7 Million - $17.3 Million	-110,000 Reduced 44.82%	135,400 $15.5 Million
Q1 2023 May 15, 2023	SELL	$117.53 - $155.99 $19.2 Million - $25.5 Million	-163,700 Reduced 40.01%	245,400 $33.8 Million
Q4 2022 Feb 14, 2023	BUY	$100.86 - $132.13 $2.98 Million - $3.9 Million	29,500 Added 7.77%	409,100 $53 Million
Q3 2022 Nov 14, 2022	BUY	$75.71 - $119.24 $7.63 Million - $12 Million	100,800 Added 36.15%	379,600 $42 Million
Q2 2022 Aug 15, 2022	BUY	$62.69 - $88.44 $7.07 Million - $9.97 Million	112,700 Added 67.85%	278,800 $20.9 Million
Q1 2022 May 16, 2022	BUY	$63.15 - $90.42 $7.71 Million - $11 Million	122,100 Added 277.5%	166,100 $13 Million
Q4 2021 Feb 14, 2022	SELL	$77.28 - $99.42 $1.39 Million - $1.79 Million	-18,000 Reduced 29.03%	44,000 $3.96 Million
Q3 2021 Nov 15, 2021	BUY	$65.97 - $92.48 $4.09 Million - $5.73 Million	62,000 New	62,000 $5.73 Million

528

84M

2.06M

1.52M

Ticker SRPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,567,904
Market Cap $10.2B
Description
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Balyasny Asset Management LLC with notifications on news.